Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.

Commons RJ, Simpson JA, Thriemer K, Chu CS, Douglas NM, Abreha T, Alemu SG, Añez A, Anstey NM, Aseffa A, Assefa A, Awab GR, Baird JK, Barber BE, Borghini-Fuhrer I, D'Alessandro U, Dahal P, Daher A, de Vries PJ, Erhart A, Gomes MSM, Grigg MJ, Hwang J, Kager PA, Ketema T, Khan WA, Lacerda MVG, Leslie T, Ley B, Lidia K, Monteiro WM, Pereira DB, Phan GT, Phyo AP, Rowland M, Saravu K, Sibley CH, Siqueira AM, Stepniewska K, Taylor WRJ, Thwaites G, Tran BQ, Hien TT, Vieira JLF, Wangchuk S, Watson J, William T, Woodrow CJ, Nosten F, Guerin PJ, White NJ, Price RN.

BMC Med. 2019 Aug 1;17(1):151. doi: 10.1186/s12916-019-1386-6.

2.

Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-label, superiority trial.

Ahmed R, Poespoprodjo JR, Syafruddin D, Khairallah C, Pace C, Lukito T, Maratina SS, Asih PBS, Santana-Morales MA, Adams ER, Unwin VT, Williams CT, Chen T, Smedley J, Wang D, Faragher B, Price RN, Ter Kuile FO.

Lancet Infect Dis. 2019 Jul 25. pii: S1473-3099(19)30156-2. doi: 10.1016/S1473-3099(19)30156-2. [Epub ahead of print]

3.

Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.

Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, Auburn S, Chand K, Chau NH, Cheah PY, Dong LT, Dhorda M, Degaga TS, Devine A, Ekawati LL, Fahmi F, Hailu A, Hasanzai MA, Hien TT, Khu H, Ley B, Lubell Y, Marfurt J, Mohammad H, Moore KA, Naddim MN, Pasaribu AP, Pasaribu S, Promnarate C, Rahim AG, Sirithiranont P, Solomon H, Sudoyo H, Sutanto I, Thanh NV, Tuyet-Trinh NT, Waithira N, Woyessa A, Yamin FY, Dondorp A, Simpson JA, Baird JK, White NJ, Day NP, Price RN.

Lancet. 2019 Jul 18. pii: S0140-6736(19)31285-1. doi: 10.1016/S0140-6736(19)31285-1. [Epub ahead of print]

4.

Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study.

Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, Pfeffer DA, Cameron E, Rao PC, Casey D, Gibson HS, Rozier JA, Dalrymple U, Keddie SH, Collins EL, Harris JR, Guerra CA, Thorn MP, Bisanzio D, Fullman N, Huynh CK, Kulikoff X, Kutz MJ, Lopez AD, Mokdad AH, Naghavi M, Nguyen G, Shackelford KA, Vos T, Wang H, Lim SS, Murray CJL, Price RN, Baird JK, Smith DL, Bhatt S, Weiss DJ, Hay SI, Gething PW.

Lancet. 2019 Jul 27;394(10195):332-343. doi: 10.1016/S0140-6736(19)31096-7. Epub 2019 Jun 19.

5.

Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study.

Kenangalem E, Poespoprodjo JR, Douglas NM, Burdam FH, Gdeumana K, Chalfein F, Prayoga, Thio F, Devine A, Marfurt J, Waramori G, Yeung S, Noviyanti R, Penttinen P, Bangs MJ, Sugiarto P, Simpson JA, Soenarto Y, Anstey NM, Price RN.

PLoS Med. 2019 May 29;16(5):e1002815. doi: 10.1371/journal.pmed.1002815. eCollection 2019 May.

6.

Evaluating antimalarial efficacy in single-armed and comparative drug trials using competing risk survival analysis: a simulation study.

Dahal P, Guerin PJ, Price RN, Simpson JA, Stepniewska K.

BMC Med Res Methodol. 2019 May 17;19(1):107. doi: 10.1186/s12874-019-0748-2.

7.

Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia.

Setyadi A, Arguni E, Kenangalem E, Hasanuddin A, Lampah DA, Thriemer K, Anstey NM, Sugiarto P, Simpson JA, Price RN, Douglas NM, Poespoprodjo JR.

Malar J. 2019 Apr 2;18(1):111. doi: 10.1186/s12936-019-2745-7.

8.

Glycocalyx Breakdown is Associated with Severe Disease and Fatal Outcome in Plasmodium falciparum Malaria.

Yeo TW, Weinberg JB, Lampah DA, Kenangalem E, Bush P, Chen Y, Price RN, Young S, Zhang HY, Millington D, Granger DL, Anstey NM.

Clin Infect Dis. 2019 Feb 12. doi: 10.1093/cid/ciz038. [Epub ahead of print]

PMID:
30753363
9.

3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.

Xue L, Shi DH, Harjani JR, Huang F, Beveridge JG, Dingjan T, Ban K, Diab S, Duffy S, Lucantoni L, Fletcher S, Chiu FCK, Blundell S, Ellis K, Ralph SA, Wirjanata G, Teguh S, Noviyanti R, Chavchich M, Creek D, Price RN, Marfurt J, Charman SA, Cuellar ME, Strasser JM, Dahlin JL, Walters MA, Edstein MD, Avery VM, Baell JB.

J Med Chem. 2019 Mar 14;62(5):2485-2498. doi: 10.1021/acs.jmedchem.8b01799. Epub 2019 Mar 5.

PMID:
30715882
10.

Growing evidence of Plasmodium vivax across malaria-endemic Africa.

Twohig KA, Pfeffer DA, Baird JK, Price RN, Zimmerman PA, Hay SI, Gething PW, Battle KE, Howes RE.

PLoS Negl Trop Dis. 2019 Jan 31;13(1):e0007140. doi: 10.1371/journal.pntd.0007140. eCollection 2019 Jan. Erratum in: PLoS Negl Trop Dis. 2019 Jun 28;13(6):e0007525.

11.

Genomic analysis of Plasmodium vivax in southern Ethiopia reveals selective pressures in multiple parasite mechanisms.

Auburn S, Getachew S, Pearson RD, Amato R, Miotto O, Trimarsanto H, Zhu SJ, Rumaseb A, Marfurt J, Noviyanti R, Grigg MJ, Barber B, William T, Goncalves SM, Drury E, Sriprawat K, Anstey NM, Nosten F, Petros B, Aseffa A, McVean G, Kwiatkowski DP, Price RN.

J Infect Dis. 2019 Jan 21. doi: 10.1093/infdis/jiz016. [Epub ahead of print]

PMID:
30668735
12.

Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis.

Commons RJ, Simpson JA, Thriemer K, Hossain MS, Douglas NM, Humphreys GS, Sibley CH, Guerin PJ, Price RN.

Lancet Infect Dis. 2019 Jan;19(1):91-101. doi: 10.1016/S1473-3099(18)30596-6.

13.

Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance.

Grigg MJ, William T, Piera KA, Rajahram GS, Jelip J, Aziz A, Menon J, Marfurt J, Price RN, Auburn S, Barber BE, Yeo TW, Anstey NM.

Malar J. 2018 Dec 10;17(1):463. doi: 10.1186/s12936-018-2593-x.

14.

Spectrophotometry assays to determine G6PD activity from Trinity Biotech and Pointe Scientific G6PD show good correlation.

Alam MS, Kibria MG, Jahan N, Price RN, Ley B.

BMC Res Notes. 2018 Dec 4;11(1):855. doi: 10.1186/s13104-018-3964-7.

15.

Circulating Neutrophil Extracellular Traps and Neutrophil Activation Are Increased in Proportion to Disease Severity in Human Malaria.

Kho S, Minigo G, Andries B, Leonardo L, Prayoga P, Poespoprodjo JR, Kenangalem E, Price RN, Woodberry T, Anstey NM, Yeo TW.

J Infect Dis. 2019 May 24;219(12):1994-2004. doi: 10.1093/infdis/jiy661.

16.

Loss of complement regulatory proteins on uninfected erythrocytes in vivax and falciparum malaria anemia.

Oyong DA, Kenangalem E, Poespoprodjo JR, Beeson JG, Anstey NM, Price RN, Boyle MJ.

JCI Insight. 2018 Nov 15;3(22). pii: 124854. doi: 10.1172/jci.insight.124854.

17.

Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity.

Alam MS, Kibria MG, Jahan N, Thriemer K, Hossain MS, Douglas NM, Phru CS, Khan WA, Price RN, Ley B.

PLoS One. 2018 Nov 2;13(11):e0206331. doi: 10.1371/journal.pone.0206331. eCollection 2018.

18.

Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria".

Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Gonzàlez Cabrera D, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz LM, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01941-18. doi: 10.1128/AAC.01941-18. Print 2018 Nov. No abstract available.

19.

Correction: Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial.

Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, Assef A, Kassa M, Chatfield MD, Landman KZ, Chenet SM, Lucchi NW, Udhayakumar V, Zhou Z, Shi YP, Kachur SP, Jima D, Kebede A, Solomon H, Mekasha A, Alemayehu BH, Malone JL, Dissanayake G, Teka H, Auburn S, Seidlein LV, Price RN.

PLoS Med. 2018 Oct 4;15(10):e1002677. doi: 10.1371/journal.pmed.1002677. eCollection 2018 Oct.

20.

Plasmodium falciparum Activates CD16+ Dendritic Cells to Produce Tumor Necrosis Factor and Interleukin-10 in Subpatent Malaria.

Loughland JR, Woodberry T, Boyle MJ, Tipping PE, Piera KA, Amante FH, Kenangalem E, Price RN, Engwerda CR, Anstey NM, McCarthy JS, Minigo G.

J Infect Dis. 2019 Jan 29;219(4):660-671. doi: 10.1093/infdis/jiy555.

21.

Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating Plasmodium falciparum Malaria Patients Using Mathematical Modeling.

Dini S, Zaloumis S, Cao P, Price RN, Fowkes FJI, van der Pluijm RW, McCaw JM, Simpson JA.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01068-18. doi: 10.1128/AAC.01068-18. Print 2018 Nov.

22.

Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model.

Scott N, Ataide R, Wilson DP, Hellard M, Price RN, Simpson JA, Fowkes FJI.

Malar J. 2018 Aug 2;17(1):279. doi: 10.1186/s12936-018-2418-y.

23.

The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis.

Commons RJ, Simpson JA, Thriemer K, Humphreys GS, Abreha T, Alemu SG, Añez A, Anstey NM, Awab GR, Baird JK, Barber BE, Borghini-Fuhrer I, Chu CS, D'Alessandro U, Dahal P, Daher A, de Vries PJ, Erhart A, Gomes MSM, Gonzalez-Ceron L, Grigg MJ, Heidari A, Hwang J, Kager PA, Ketema T, Khan WA, Lacerda MVG, Leslie T, Ley B, Lidia K, Monteiro WM, Nosten F, Pereira DB, Phan GT, Phyo AP, Rowland M, Saravu K, Sibley CH, Siqueira AM, Stepniewska K, Sutanto I, Taylor WRJ, Thwaites G, Tran BQ, Tran HT, Valecha N, Vieira JLF, Wangchuk S, William T, Woodrow CJ, Zuluaga-Idarraga L, Guerin PJ, White NJ, Price RN.

Lancet Infect Dis. 2018 Sep;18(9):1025-1034. doi: 10.1016/S1473-3099(18)30348-7. Epub 2018 Jul 20.

24.

Platelets kill circulating parasites of all major Plasmodium species in human malaria.

Kho S, Barber BE, Johar E, Andries B, Poespoprodjo JR, Kenangalem E, Piera KA, Ehmann A, Price RN, William T, Woodberry T, Foote S, Minigo G, Yeo TW, Grigg MJ, Anstey NM, McMorran BJ.

Blood. 2018 Sep 20;132(12):1332-1344. doi: 10.1182/blood-2018-05-849307. Epub 2018 Jul 19.

25.

Genomic analysis of a pre-elimination Malaysian Plasmodium vivax population reveals selective pressures and changing transmission dynamics.

Auburn S, Benavente ED, Miotto O, Pearson RD, Amato R, Grigg MJ, Barber BE, William T, Handayuni I, Marfurt J, Trimarsanto H, Noviyanti R, Sriprawat K, Nosten F, Campino S, Clark TG, Anstey NM, Kwiatkowski DP, Price RN.

Nat Commun. 2018 Jul 3;9(1):2585. doi: 10.1038/s41467-018-04965-4.

26.

UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.

Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Cabrera DG, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz LM, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00012-18. doi: 10.1128/AAC.00012-18. Print 2018 Sep. Erratum in: Antimicrob Agents Chemother. 2018 Oct 24;62(11):.

27.

Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group.

Thriemer K, Bobogare A, Ley B, Gudo CS, Alam MS, Anstey NM, Ashley E, Baird JK, Gryseels C, Jambert E, Lacerda M, Laihad F, Marfurt J, Pasaribu AP, Poespoprodjo JR, Sutanto I, Taylor WR, van den Boogaard C, Battle KE, Dysoley L, Ghimire P, Hawley B, Hwang J, Khan WA, Mudin RNB, Sumiwi ME, Ahmed R, Aktaruzzaman MM, Awasthi KR, Bardaji A, Bell D, Boaz L, Burdam FH, Chandramohan D, Cheng Q, Chindawongsa K, Culpepper J, Das S, Deray R, Desai M, Domingo G, Duoquan W, Duparc S, Floranita R, Gerth-Guyette E, Howes RE, Hugo C, Jagoe G, Sariwati E, Jhora ST, Jinwei W, Karunajeewa H, Kenangalem E, Lal BK, Landuwulang C, Le Perru E, Lee SE, Makita LS, McCarthy J, Mekuria A, Mishra N, Naket E, Nambanya S, Nausien J, Duc TN, Thi TN, Noviyanti R, Pfeffer D, Qi G, Rahmalia A, Rogerson S, Samad I, Sattabongkot J, Satyagraha A, Shanks D, Sharma SN, Sibley CH, Sungkar A, Syafruddin D, Talukdar A, Tarning J, Ter Kuile F, Thapa S, Theodora M, Huy TT, Waramin E, Waramori G, Woyessa A, Wongsrichanalai C, Xa NX, Yeom JS, Hermawan L, Devine A, Nowak S, Jaya I, Supargiyono S, Grietens KP, Price RN.

Malar J. 2018 Jun 20;17(1):241. doi: 10.1186/s12936-018-2380-8.

28.

Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.

Kloprogge F, Workman L, Borrmann S, Tékété M, Lefèvre G, Hamed K, Piola P, Ursing J, Kofoed PE, Mårtensson A, Ngasala B, Björkman A, Ashton M, Friberg Hietala S, Aweeka F, Parikh S, Mwai L, Davis TME, Karunajeewa H, Salman S, Checchi F, Fogg C, Newton PN, Mayxay M, Deloron P, Faucher JF, Nosten F, Ashley EA, McGready R, van Vugt M, Proux S, Price RN, Karbwang J, Ezzet F, Bakshi R, Stepniewska K, White NJ, Guerin PJ, Barnes KI, Tarning J.

PLoS Med. 2018 Jun 12;15(6):e1002579. doi: 10.1371/journal.pmed.1002579. eCollection 2018 Jun.

29.

High Risk of Plasmodium vivax Malaria Following Splenectomy in Papua, Indonesia.

Kho S, Andries B, Poespoprodjo JR, Commons RJ, Shanti PAI, Kenangalem E, Douglas NM, Simpson JA, Sugiarto P, Anstey NM, Price RN.

Clin Infect Dis. 2019 Jan 1;68(1):51-60. doi: 10.1093/cid/ciy403.

30.

Malaria Elimination: Time to Target All Species.

Lover AA, Baird JK, Gosling R, Price RN.

Am J Trop Med Hyg. 2018 Jul;99(1):17-23. doi: 10.4269/ajtmh.17-0869. Epub 2018 May 10.

31.

Expanding the Use of Primaquine for the Radical Cure of Plasmodium vivax.

Price RN, Douglas NM.

Clin Infect Dis. 2018 Sep 14;67(7):1008-1009. doi: 10.1093/cid/ciy236. No abstract available.

32.

Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan.

Hamid MMA, Thriemer K, Elobied ME, Mahgoub NS, Boshara SA, Elsafi HMH, Gumaa SA, Hamid T, Abdelbagi H, Basheir HM, Marfurt J, Chen I, Gosling R, Price RN, Ley B.

Malar J. 2018 Mar 16;17(1):117. doi: 10.1186/s12936-018-2266-9.

33.

The Plasmodium falciparum transcriptome in severe malaria reveals altered expression of genes involved in important processes including surface antigen-encoding var genes.

Tonkin-Hill GQ, Trianty L, Noviyanti R, Nguyen HHT, Sebayang BF, Lampah DA, Marfurt J, Cobbold SA, Rambhatla JS, McConville MJ, Rogerson SJ, Brown GV, Day KP, Price RN, Anstey NM, Papenfuss AT, Duffy MF.

PLoS Biol. 2018 Mar 12;16(3):e2004328. doi: 10.1371/journal.pbio.2004328. eCollection 2018 Mar.

34.

The ethics of using placebo in randomised controlled trials: a case study of a Plasmodium vivax antirelapse trial.

Cheah PY, Steinkamp N, von Seidlein L, Price RN.

BMC Med Ethics. 2018 Mar 6;19(1):19. doi: 10.1186/s12910-018-0259-4.

35.

Drugs that reduce transmission of falciparum malaria.

Price RN, White NJ.

Lancet Infect Dis. 2018 Jun;18(6):585-586. doi: 10.1016/S1473-3099(18)30070-7. Epub 2018 Feb 6. No abstract available.

36.

Therapeutic Response to Dihydroartemisinin-Piperaquine for P. falciparum and P. vivax Nine Years after Its Introduction in Southern Papua, Indonesia.

Poespoprodjo JR, Kenangalem E, Wafom J, Chandrawati F, Puspitasari AM, Ley B, Trianty L, Korten Z, Surya A, Syafruddin D, Anstey NM, Marfurt J, Noviyanti R, Price RN.

Am J Trop Med Hyg. 2018 Mar;98(3):677-682. doi: 10.4269/ajtmh.17-0662. Epub 2018 Jan 11.

37.

Treatment-Seeking Behavior after the Implementation of a Unified Policy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Papua, Indonesia.

Devine A, Kenangalem E, Burdam FH, Anstey NM, Poespoprodjo JR, Price RN, Yeung S.

Am J Trop Med Hyg. 2018 Feb;98(2):543-550. doi: 10.4269/ajtmh.17-0680. Epub 2017 Dec 21.

38.

Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges.

Dahal P, Simpson JA, Dorsey G, Guérin PJ, Price RN, Stepniewska K.

Malar J. 2017 Oct 26;16(1):430. doi: 10.1186/s12936-017-2074-7. Review.

39.

Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW.

Grigg MJ, William T, Barber BE, Rajahram GS, Menon J, Schimann E, Wilkes CS, Patel K, Chandna A, Price RN, Yeo TW, Anstey NM.

Clin Infect Dis. 2018 Jan 6;66(2):229-236. doi: 10.1093/cid/cix779.

40.

Passively versus Actively Detected Malaria: Similar Genetic Diversity but Different Complexity of Infection.

Pava Z, Handayuni I, Trianty L, Utami RAS, Tirta YK, Puspitasari AM, Burdam F, Kenangalem E, Wirjanata G, Kho S, Trimarsanto H, Anstey N, Poespoprodjo JR, Noviyanti R, Price RN, Marfurt J, Auburn S.

Am J Trop Med Hyg. 2017 Dec;97(6):1788-1796. doi: 10.4269/ajtmh.17-0364. Epub 2017 Aug 31.

41.

Methods for the field evaluation of quantitative G6PD diagnostics: a review.

Ley B, Bancone G, von Seidlein L, Thriemer K, Richards JS, Domingo GJ, Price RN.

Malar J. 2017 Sep 11;16(1):361. doi: 10.1186/s12936-017-2017-3. Review.

42.

Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.

Douglas NM, Poespoprodjo JR, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, Simpson JA, Soenarto Y, Anstey NM, Price RN.

PLoS Med. 2017 Aug 29;14(8):e1002379. doi: 10.1371/journal.pmed.1002379. eCollection 2017 Aug.

43.

Molecular analysis demonstrates high prevalence of chloroquine resistance but no evidence of artemisinin resistance in Plasmodium falciparum in the Chittagong Hill Tracts of Bangladesh.

Alam MS, Ley B, Nima MK, Johora FT, Hossain ME, Thriemer K, Auburn S, Marfurt J, Price RN, Khan WA.

Malar J. 2017 Aug 15;16(1):335. doi: 10.1186/s12936-017-1995-5.

44.

Barriers to routine G6PD testing prior to treatment with primaquine.

Ley B, Thriemer K, Jaswal J, Poirot E, Alam MS, Phru CS, Khan WA, Dysoley L, Qi G, Kheong CC, Shamsudin UK, Chen I, Hwang J, Gosling R, Price RN.

Malar J. 2017 Aug 10;16(1):329. doi: 10.1186/s12936-017-1981-y.

45.

Chloroquine efficacy for Plasmodium vivax in Myanmar in populations with high genetic diversity and moderate parasite gene flow.

Htun MW, Mon NCN, Aye KM, Hlaing CM, Kyaw MP, Handayuni I, Trimarsanto H, Bustos D, Ringwald P, Price RN, Auburn S, Thriemer K.

Malar J. 2017 Jul 10;16(1):281. doi: 10.1186/s12936-017-1912-y.

46.

Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis.

Devine A, Parmiter M, Chu CS, Bancone G, Nosten F, Price RN, Lubell Y, Yeung S.

PLoS Negl Trop Dis. 2017 May 24;11(5):e0005602. doi: 10.1371/journal.pntd.0005602. eCollection 2017 May.

47.

A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.

O'Neill PM, Amewu RK, Charman SA, Sabbani S, Gnädig NF, Straimer J, Fidock DA, Shore ER, Roberts NL, Wong MH, Hong WD, Pidathala C, Riley C, Murphy B, Aljayyoussi G, Gamo FJ, Sanz L, Rodrigues J, Cortes CG, Herreros E, Angulo-Barturén I, Jiménez-Díaz MB, Bazaga SF, Martínez-Martínez MS, Campo B, Sharma R, Ryan E, Shackleford DM, Campbell S, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Palmer MJ, Copple IM, Mercer AE, Ruecker A, Delves MJ, Sinden RE, Siegl P, Davies J, Rochford R, Kocken CHM, Zeeman AM, Nixon GL, Biagini GA, Ward SA.

Nat Commun. 2017 May 24;8:15159. doi: 10.1038/ncomms15159.

48.

Plasmodium falciparum and Plasmodium vivax Demonstrate Contrasting Chloroquine Resistance Reversal Phenotypes.

Wirjanata G, Handayuni I, Prayoga P, Leonardo L, Apriyanti D, Trianty L, Wandosa R, Gobay B, Kenangalem E, Poespoprodjo JR, Noviyanti R, Kyle DE, Cheng Q, Price RN, Marfurt J.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00355-17. doi: 10.1128/AAC.00355-17. Print 2017 Aug.

49.

Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial.

Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, Assef A, Kassa M, Chatfield MD, Landman KZ, Chenet SM, Lucchi NW, Udhayakumar V, Zhou Z, Shi YP, Kachur SP, Jima D, Kebede A, Solomon H, Mekasha A, Alemayehu BH, Malone JL, Dissanayake G, Teka H, Auburn S, von Seidlein L, Price RN.

PLoS Med. 2017 May 16;14(5):e1002299. doi: 10.1371/journal.pmed.1002299. eCollection 2017 May. Erratum in: PLoS Med. 2018 Oct 4;15(10):e1002677.

50.

Genetic micro-epidemiology of malaria in Papua Indonesia: Extensive P. vivax diversity and a distinct subpopulation of asymptomatic P. falciparum infections.

Pava Z, Noviyanti R, Handayuni I, Trimarsanto H, Trianty L, Burdam FH, Kenangalem E, Utami RAS, Tirta YK, Coutrier F, Poespoprodjo JR, Price RN, Marfurt J, Auburn S.

PLoS One. 2017 May 12;12(5):e0177445. doi: 10.1371/journal.pone.0177445. eCollection 2017.

Supplemental Content

Loading ...
Support Center